Table 2.

List of revisions to the company base case after the second Appraisal Consultation Document

Change #	Description
1	Second enhanced PAS discount
2	Updated utility inputs for PFS1 (3L mapped EQ-5D utilities from the MONALEESA-2) and PFS2 (from Mitra et al. [35])
3	PFS (local assessment) and TTD exponential extrapolation for the first-line treatment, both based on a January 2017 data cut-off
4	£1500 as the treatment cost estimate for third and later lines

PAS patient access scheme, PFS progression-free survival, PFS1 first-line progression-free survival, PFS2 second-line progression-free survival, TTD time to treatment discontinuation